A high pretreatment plasma oestradiol level is associated with a low risk of acute myocardial infarction in parenteral oestrogen therapy for locally advanced prostate cancer

BJU International

Volumn 101, Issue 9, 2008, Pages 1090-1095

  Mikkola, Arto K K ^a   Aro, Jussi L V ^a   Rannikko, A S Sakari ^a   Ruutu, Mirja L ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Androgen deprivation; Cardiovascular; Complications; Orchidectomy; Polyoestradiol phosphate; Therapy

Indexed keywords

ESTRADIOL; POLYESTRADIOL PHOSPHATE; TESTOSTERONE;

ACUTE HEART INFARCTION; ADVANCED CANCER; AGED; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; ESTRADIOL; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, PARENTERAL; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ORCHIECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; TESTOSTERONE; TREATMENT OUTCOME;

EID: 41849093032     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07361.x     Document Type: Article

References (30)

1. Cox RL, Crawford ED. Estrogens in the treatment of prostate cancer. J Urol 1995 154 : 1991 8
2. Mikkola AK, Ruutu ML, Aro JL, Rannikko SA, Salo JO. Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Finnprostate Group. Br J Urol 1998 82 : 63 8
3. Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD. Transdermal estradiol therapy for advanced prostate cancer - forward to the past? J Urol 2003 169 : 1735 7
4. Hedlund PO, Ala-Opas M, Brekkan E et al. Scandinavian Prostatic Cancer Group. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer - Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2002 36 : 405
5. Mikkola A, Aro J, Rannikko S, Oksanen H, Ruutu M. Finnprostate group. Cardiovascular complications in patients with advanced prostatic cancer treated by means of orchiectomy or polyestradiol phosphate. Scand J Urol Nephrol 2005 39 : 294 300
6. Mikkola A, Aro J, Rannikko S, Ruutu M, Finnprostate Group. Ten-year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy. Prostate 2007 67 : 447 55
7. Muller M, van der Schouw YT, Thijssen JH, Grobbee DE. Endogenous sex hormones and cardiovascular disease in men. J Clin Endocrinol Metab 2003 88 : 5076 86
8. Mikkola AK, Aro JL, Rannikko SA, Salo JO. Pretreatment plasma testosterone and estradiol levels in patients with locally advanced or metastasized prostatic cancer. Finnprostate Group. Prostate 1999 39 : 175 81
9. Simpson ER. Role of aromatase in sex steroid action. J Mol Endocrinol 2000 25 : 149 56
10. Harada N, Sasano H, Murakami H, Ohkuma T, Nagura H, Takagi Y. Localized expression of aromatase in human vascular tissues. Circ Res 1999 84 : 1285 91
11. Orwoll E, Lambert LC, Marshall LM et al. Testosterone and estradiol among older men. J Clin Endocrinol Metab 2006 91 : 1336 44
12. Muller M, den Tonkelaar I, Thijssen JH, Grobbee DE, van der Schouw YT. Endogenous sex hormones in men aged 40-80 years. Eur J Endocrinol 2003 149 : 583 9
13. Bjornarem A, Straume B, Midtby M et al. Endogenous sex hormones in relation to age, sex, lifestyle factors, and chronic diseases in a general population: the Tromso Study. J Clin Endocrinol Metab 2004 89 : 6039 47
14. Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A, Pols HA. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab 2002 87 : 3632 9
15. Maffei L, Murata Y, Rochira V et al. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab 2004 89 : 61 70
16. Sudhir K, Chou TM, Chatterjee K et al. Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation 1997 96 : 3774 7
17. Liu PY, Christian RC, Ruan M, Miller VM, Fitzpatrick LA. Correlating androgen and estrogen steroid receptor expression with coronary calcification and atherosclerosis in men without known coronary artery disease. J Clin Endocrinol Metab 2005 90 : 1041 6
18. Arnlov J, Pencina MJ, Amin S et al. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med 2006 145 : 176 84
19. Tivesten A, Hulthe J, Wallenfeldt K, Wikstrand J, Ohlsson C, Fagerberg B. Circulating estradiol is an independent predictor of progression of carotid artery intima-media thickness in middle- aged men. J Clin Endocrinol Metab 2006 91 : 4433 7
20. O'Learly DH, Polak JF, Kronmal RA, Manolio TA, Burge GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999 340 : 14 22
21. Orshal JM, Khalil RA. Gender, sex hormones, and vascular tone. Am J Physiol Regul Inregr Comp Physiol 2004 286 : R233 49
22. de Ronde W, Pols HA, van Leeuwen JP, de Jong FH. The importance of oestrogens in males. Clin Endocrinol 2003 58 : 529 42
23. Lew R, Komesaroff P, Williams M, Dawood T, Sudhir K. Endogenous estrogens influence endothelial function in young men. Circ Res 2003 93 : 1127 33
24. Blumenthal RS, Heldman AW, Brinker JA et al. Acute effects of conjugated estrogens on coronary blood flow response to acetylcholine in men. Am J Cardiol 1997 80 : 1021 4
25. Reis SE, Holubkov R, Zell KA et al. Estrogen acutely abolishes abnormal cold-induced coronary constriction in men. Chest 1998 114 : 1556 61
26. Carlstrom K, Stege R, Henriksson P, Grande M, Gunnarsson PO, Pousette A. Possible bone-preserving capacity of high-dose intramuscular depot estrogen as compared to orchidectomy in the treatment of patients with prostatic carcinoma. Prostate 1997 31 : 193 7
27. Ockrim JL, Lalani el-N, Aslam M, Standfield N, Abel PD. Changes in vascular flow after transdermal oestradiol therapy for prostate cancer: a mechanism for cardiovascular toxicity and benefit? BJU Int 2006 97 : 498 504
28. Komesaroff PA, Fullerton M, Esler MD, Dart A, Jennings G, Sudhir K. Low-dose estrogen supplementation improves vascular function in hypogonadal men. Hypertension 2001 38 : 1011 6
29. Mukamal KJ, Chiuve SE, Rimm EB. Alcohol consumption and risk for coronary heart disease in men with healthy lifestyles. Arch Intern Med 2006 166 : 2145 50
30. Bagatell CJ, Knopp RH, Rivier JE, Bremner WJ. Physiological levels of estradiol stimulate plasma high density lipoprotein2 cholesterol levels in normal men. J Clin Endocrinol Metab 1994 78 : 855 61